Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Amneal Expects Fiscal Year 2024 Adjusted EBITDA Of $580M-$620M, With Operating Cash Flow Of $260M-$300M And Capital Expenditures Of $60M-$70M Compared To $558M, $346M, and $43M In 2023, Respectively

Author: Benzinga Newsdesk | March 01, 2024 07:09am

Posted In: AMRX